RxSight (RXST) Stock Overview
A commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
RXST Community Fair Values
Create NarrativeSee what 11 others think this stock is worth. Follow their fair value or set your own to get alerts.
RxSight, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$13.61 |
| 52 Week High | US$60.81 |
| 52 Week Low | US$12.53 |
| Beta | 1.29 |
| 1 Month Change | -13.20% |
| 3 Month Change | -45.39% |
| 1 Year Change | -76.01% |
| 3 Year Change | -2.44% |
| 5 Year Change | n/a |
| Change since IPO | -14.94% |
Recent News & Updates
The Price Is Right For RxSight, Inc. (NASDAQ:RXST)
Jun 18
RxSight: Valuation Blowout Creates Opportunity
Jun 07
South Korea And UK Approvals Will Expand Market Adoption
International expansion and regulatory approvals are poised to significantly boost revenue by entering new markets and enhancing clinical support.RxSight (NASDAQ:RXST) Is In A Strong Position To Grow Its Business
Apr 04Recent updates
The Price Is Right For RxSight, Inc. (NASDAQ:RXST)
Jun 18RxSight: Valuation Blowout Creates Opportunity
Jun 07South Korea And UK Approvals Will Expand Market Adoption
International expansion and regulatory approvals are poised to significantly boost revenue by entering new markets and enhancing clinical support.RxSight (NASDAQ:RXST) Is In A Strong Position To Grow Its Business
Apr 04RxSight, Inc. (NASDAQ:RXST) Shares Slammed 27% But Getting In Cheap Might Be Difficult Regardless
Mar 08RxSight, Inc. (NASDAQ:RXST) Just Reported, And Analysts Assigned A US$44.80 Price Target
Feb 28The Price Is Right For RxSight, Inc. (NASDAQ:RXST)
Dec 06RxSight's Momentum In The Large Cataract Surgery Market Merits A Close Eye
Nov 29We Think RxSight (NASDAQ:RXST) Can Easily Afford To Drive Business Growth
Sep 04Investing In The Future Of Cataract Surgery: The RxSight Advantage
Aug 13With A 27% Price Drop For RxSight, Inc. (NASDAQ:RXST) You'll Still Get What You Pay For
Aug 03Why RxSight, Inc. (NASDAQ:RXST) Could Be Worth Watching
Jul 12RxSight: Great Business Model, Stretched Valuations
Jul 10A Look At The Intrinsic Value Of RxSight, Inc. (NASDAQ:RXST)
Jun 20RxSight, Inc. (NASDAQ:RXST) Analysts Are Pretty Bullish On The Stock After Recent Results
May 09RxSight (NASDAQ:RXST) Is In A Strong Position To Grow Its Business
May 05RxSight: Promising Technology, Uncertain Profitability - A Hold Recommendation
May 01Why We're Not Concerned About RxSight, Inc.'s (NASDAQ:RXST) Share Price
Apr 16Is It Time To Consider Buying RxSight, Inc. (NASDAQ:RXST)?
Mar 24RxSight Stock: Time To Refocus Following Eye Watering Rally
Jan 16RxSight, Inc. (NASDAQ:RXST) Stocks Shoot Up 30% But Its P/S Still Looks Reasonable
Jan 09We Think RxSight (NASDAQ:RXST) Can Afford To Drive Business Growth
Dec 21Revenues Tell The Story For RxSight, Inc. (NASDAQ:RXST) As Its Stock Soars 28%
Nov 24RxSight, Inc. (NASDAQ:RXST) Just Reported And Analysts Have Been Lifting Their Price Targets
Aug 11RxSight Non-GAAP EPS of -$0.50 beats by $0.15, revenue of $11.4M beats by $0.85M
Aug 08RxSight says FDA requires additional info for approval of light delivery device
Jul 12Shareholder Returns
| RXST | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -4.2% | -0.7% | 0.0005% |
| 1Y | -76.0% | 5.5% | 10.0% |
Return vs Industry: RXST underperformed the US Medical Equipment industry which returned 5.5% over the past year.
Return vs Market: RXST underperformed the US Market which returned 10% over the past year.
Price Volatility
| RXST volatility | |
|---|---|
| RXST Average Weekly Movement | 14.5% |
| Medical Equipment Industry Average Movement | 8.6% |
| Market Average Movement | 7.7% |
| 10% most volatile stocks in US Market | 17.4% |
| 10% least volatile stocks in US Market | 4.0% |
Stable Share Price: RXST's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: RXST's weekly volatility has increased from 9% to 14% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 498 | Ron Kurtz | www.rxsight.com |
RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company’s RxSight system includes RxSight Light Adjustable Lens (LAL), an intraocular lens made of photosensitive material that changes shape in response to specific patterns of ultraviolet, which can be adjusted to improve uncorrected visual acuity; and RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery.
RxSight, Inc. Fundamentals Summary
| RXST fundamental statistics | |
|---|---|
| Market cap | US$553.07m |
| Earnings (TTM) | -US$26.54m |
| Revenue (TTM) | US$148.31m |
Is RXST overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RXST income statement (TTM) | |
|---|---|
| Revenue | US$148.31m |
| Cost of Revenue | US$41.72m |
| Gross Profit | US$106.59m |
| Other Expenses | US$133.13m |
| Earnings | -US$26.54m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.65 |
| Gross Margin | 71.87% |
| Net Profit Margin | -17.90% |
| Debt/Equity Ratio | 0% |
How did RXST perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/22 14:02 |
| End of Day Share Price | 2025/06/20 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
RxSight, Inc. is covered by 13 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Craig Bijou | BofA Global Research |
| Michael Gorman | BTIG |
| Xuyang Li | Jefferies LLC |